Abstract:Background and importance First-generation Janus kinase inhibitors (JAKi), tofacitinib and baricitinib, are approved in adults with moderately to severely active rheumatoid arthritis (RA) who have not responded or tolerated previous treatment lines. Real clinical data about persistence and therapeutic adherence to these treatments is scarce. Aim and objectives (i) To assess and compare first-generation JAKi persistence in clinical practice. (ii) To compare whether therapeutic adherence to tofacitinib and baric… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.